Get started
Author

Jose F Saraiva

Observed names: J F K S Saraiva, J.F. Saraiva, JOSE FRANCISCO KERR SARAIVA
OpenAlex ID: A5063380442
Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
2023 · M. Witzenrath, A.P.J. Vlaar, et al. · 2
Awareness and perceptions of cardiologists towards systemic inflammation in atherosclerotic cardiovascular disease: A multi-national survey across 5 geographical regional sub-groups
2024 · A Catapano, I K Komuro, et al. · European Heart Journal · 1
PDF
Abstract 13678: Initial Decline in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Insights From DELIVER
2023 · Finnian R Mc Causland, Brian Claggett, et al. · Circulation
Abstract 12463: Awareness and Perceptions Towards Inflammatory Risk in Atherosclerotic Cardiovascular Disease: A Multinational Survey Amongst Cardiologists
2023 · Nikolaus Marx, Issei Komuro, et al. · Circulation
Vilobelimab Treatment Effect on 28-day All-cause Mortality in Severe Ards Covid-19 Patients in Panamo: a Phase 3 Rct
2023 · ENDRY LIM, DJILLALI ANNANE, et al. · CHEST Journal
PDF
LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia
2022 · Bruno Mourvillier, Alexander Vlaar, et al. · Open Forum Infectious Diseases
Works count: 6
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type